Treatment pathways and burden of illness models

We recognize that understanding the burden and cost of a disease provides a key foundation for any product value proposition and market access activity, and can inform decisions on how to transform and optimize patient pathways.

Whether this is an understanding of the overall cost of illness or an assessment of different treatment pathways through primary and secondary care, our team has expertise in defining the steps in a pathway, visualizing it and mapping the resources and costs used. In summary, we can support you with:

Visualising the current pathway to determine burden and cost of illness

Implementing scenarios to determine the impact of a pathway change, a new product approval, or introduction of a biomarker or diagnostic to target patients to a specific element of the pathway

Communicating the value of a new intervention to different payer, policy-maker and physician stakeholders

View a case study on a previous treatment pathways and burden of illness models project

A forecasting patient pathway model in advanced non-small cell lung cancer (NSCLC)

LEARN MORE

Health Economics & Data Analysis

Click here for details of our wider expertise and our database of published research and conference presentations

LEARN MORE

A forecasting patient pathway model in advanced non-small cell lung cancer (NSCLC)

A review of evidence informing the development of a patient pathway model to inform forecasting and identify evidence gaps

The challenge

Our client was entering the highly dynamic clinical treatment landscape for lung cancer, with a focus on precision medicine targeting specific genetic mutations. This reinforced the need to better understand the patient pathway and the proportion of patients in each clinical segment to support research and patient care decision making across the EU5, China and Japan.

The solution

Our solution followed a three-step process: > Mapping country specific epidemiology and patient pathways > Review of evidence and gap analysis > Development of a forecasting interactive patient pathway model. Given the complexity of the disease area and treatment options available, our team worked with country affiliates to ensure the patient pathway was reflective of real life.

Key results

The evidence review and gap analysis enabled development of the model, whilst also highlighted any gaps to inform further evidence generation. The model visually demonstrated the number of patients in each sub-population highlighting eligibility for specific targeted treatments at each stage of the patient pathway. Furthermore, the model generated a 5-year forecast of eligible patients for each country and each line of treatment.

Value to the client

The gap analysis clearly highlighted data gaps and included recommendations to inform planning decisions in terms of real-world evidence collection. Furthermore, the dynamic patient pathway model supported decision making through estimating eligible patient populations for five years for a new product in each treatment group across the EU5, China and Japan.